Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. (2022)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-34839-9

PubMed Identifier: 36435798

Publication URI: http://europepmc.org/abstract/MED/36435798

Type: Journal Article/Review

Volume: 13

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723